Hints and tips:
Related Special Reports
...“We don’t focus too much on the stock price,” he said. “They certainly want to see more investment . . . to realise the full potential,” he said....
...The lawsuit comes amid increased tensions between governments and pharmaceutical companies over increasing drug prices....
...Alongside Ubben, Bayer nominated Nancy Simonian, the former CEO of US biotech company Syros Pharmaceuticals, and Lori Schechter, the former general counsel of US healthcare group McKesson, to join its supervisory...
...Richer countries believe the price — around $19 a dose — means the contract remains good value for money....
...Metagenomi, a pre-clinical group backed by Moderna and Bayer, priced its $94mn IPO last week at the bottom of its target range, and fell 31 per cent on its first day of trading on Friday....
...He said chancellor Jeremy Hunt and the health department should address conflicts with the pharmaceutical industry over drug prices and hurdles to running clinical trials in the NHS....
...The US government named 10 of the best-selling drugs as the first to face tough price regulations in a bid to slash healthcare costs, marking the biggest shake-up for the pharmaceutical industry in decades...
...Under the proposed reforms, Medicare, the US taxpayer-funded healthcare scheme for retirees, would be allowed to negotiate prices for a limited number of branded medicines....
...Bayer has said it is shifting the focus of its pharmaceutical business to the US and away from Europe and the UK, where governments are making “big mistakes” in how they manage health budgets....
...The FTC warned on Tuesday that “rampant consolidation” in the pharmaceutical sector was pushing up prices for patients as it filed the lawsuit against the Amgen deal....
...healthcare and crop science....
...Healthcare should not be like this, and would not be if the patent system worked as intended....
...AbbVie and Eli Lilly have withdrawn from the deal after the German conglomerate Bayer’s pharmaceutical chief executive told the Financial Times on Monday that it was reducing its UK footprint and cutting...
...The carved-out company sold $3.8bn of stock at a price of $22 per share, giving it an initial equity valuation of $41bn....
...The head of Bayer’s drugs business warned this week the German company was shifting its pharmaceutical arm’s focus to the US, and away from Britain and European countries that were making “big mistakes”...
...Meanwhile, Germany’s Bayer in January said it was cutting jobs in Britain because of the UK medicines levy....
...US pharmaceutical company Pfizer sold the shots, developed with Germany’s BioNTech, for about $19 a dose under the contract signed in 2021, but the new price has not been disclosed....
...Haleon, GlaxoSmithKline’s consumer healthcare venture with Pfizer, is down about 5 per cent from its July listing price....
...But its pharmaceutical and medical device units — which pulled in $79bn in sales last year — continues to grow at a decent clip despite the hit from the stronger dollar....
...of pharmaceuticals for the Americas....
...Bayer, which is headquartered in Germany, told the Financial Times it will shift the focus of its pharmaceutical business to the US, accusing Europe of being “very innovation unfriendly”....
...Amgen is offering two pricing plans because in the complex US healthcare system — where the real cost of a drug tends to be decided via opaque deals — some pharmacy benefit managers prefer higher list prices...
...“If you don’t have competition then manufacturers can just run prices amok and that is what you have seen in the US, which is the single most expensive healthcare system in the world,” said Lydia Kuykendal...
...PMI chief executive Jacek Olczak told the Financial Times that Vectura’s sales had suffered because of the reluctance of pharmaceutical partners to work with the company....
...But the National Healthcare Security Administration, which negotiates drug prices for China’s national health insurance reimbursement scheme, balked at the “high price” quoted by Pfizer....
International Edition